HAPPY EASTER! 50% Off Premium Subscription Claim Offer ⏰ 0d 00h 00m 00s

DexCom Earnings Calls

Q1 2025 (Upcoming)
Release date May 01, 2025
EPS estimate $0.330
EPS actual -
Revenue estimate 1.017B
Revenue actual -
Expected change +/- 3.60%
Q4 2024 Missed
$0.450 (-6.09%)
Release date Feb 13, 2025
EPS estimate $0.479
EPS actual $0.450
EPS Surprise -6.09%
Revenue estimate 1.109B
Revenue actual 1.114B
Revenue Surprise 0.392%
Q3 2024 Beat
$0.450 (2.27%)
Release date Oct 24, 2024
EPS estimate $0.440
EPS actual $0.450
EPS Surprise 2.27%
Revenue estimate 990.443M
Revenue actual 994.2M
Revenue Surprise 0.379%
Q2 2024 Beat
$0.430 (10.26%)
Release date Jul 25, 2024
EPS estimate $0.390
EPS actual $0.430
EPS Surprise 10.26%
Revenue estimate 1.037B
Revenue actual 1.004B
Revenue Surprise -3.17%

Last 4 Quarters for DexCom

Below you can see how DXCM performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Jul 25, 2024
Fiscal end date Jun 30, 2024
Price on release $107.85
EPS estimate $0.390
EPS actual $0.430
EPS surprise 10.26%
Date Price
Jul 19, 2024 $111.66
Jul 22, 2024 $111.65
Jul 23, 2024 $112.13
Jul 24, 2024 $111.94
Jul 25, 2024 $107.85
Jul 26, 2024 $64.00
Jul 29, 2024 $67.48
Jul 30, 2024 $69.70
Jul 31, 2024 $67.82
4 days before -3.41%
4 days after -37.12%
On release day -40.66%
Change in period -39.26%
Q3 2024 Beat
Release date Oct 24, 2024
Fiscal end date Sep 30, 2024
Price on release $74.85
EPS estimate $0.440
EPS actual $0.450
EPS surprise 2.27%
Date Price
Oct 18, 2024 $72.38
Oct 21, 2024 $72.61
Oct 22, 2024 $73.08
Oct 23, 2024 $72.48
Oct 24, 2024 $74.85
Oct 25, 2024 $73.44
Oct 28, 2024 $72.10
Oct 29, 2024 $72.24
Oct 30, 2024 $71.80
4 days before 3.41%
4 days after -4.07%
On release day -1.88%
Change in period -0.80%
Q4 2024 Missed
Release date Feb 13, 2025
Fiscal end date Dec 31, 2024
Price on release $84.09
EPS estimate $0.479
EPS actual $0.450
EPS surprise -6.09%
Date Price
Feb 07, 2025 $88.08
Feb 10, 2025 $88.27
Feb 11, 2025 $86.38
Feb 12, 2025 $83.87
Feb 13, 2025 $84.09
Feb 14, 2025 $89.07
Feb 18, 2025 $90.53
Feb 19, 2025 $89.68
Feb 20, 2025 $89.34
4 days before -4.53%
4 days after 6.24%
On release day 5.92%
Change in period 1.43%
Q1 2025 (Upcoming)
Release date May 01, 2025
Fiscal end date Mar 31, 2025
Price on release -
EPS estimate $0.330
EPS actual -
Date Price
Apr 10, 2025 $67.30
Apr 11, 2025 $66.14
Apr 14, 2025 $67.39
Apr 15, 2025 $69.23
Apr 16, 2025 $68.73

DexCom Earnings Call Transcript Summary of Q4 2024

DexCom, Inc.

The company emphasized its strategic investments, international expansion, new product launches, and advancements in reimbursement, particularly for type 2 diabetes patients.

Key Financial Highlights:

  • Q4 Revenue: $1.11 billion (8% growth YoY).
  • Full-Year Revenue Growth: 12% organic growth, 14% projected for 2025.
  • Q4 US Revenue: $803 million (4% growth YoY).
  • International Revenue: Grew by 17%, totaling $311 million.
  • Operating Income: $209.5 million (18.8% of revenue).
  • Gross Profit Margin: 59.4% impacted by a $21 million non-cash charge.
  • Cash Position: Approximately $2.6 billion in cash and equivalents.

Customer Growth:

  • The global customer base grew by 25%, reaching over 2.8 million.
  • Significant improvements in sales force productivity, adding over 50,000 prescribers.

Product Developments:

  • Launched the over-the-counter product, Stella, with over 140,000 users shortly after launch.
  • Planning to launch a 15-day G7 CGM system in the second half of 2025, pending FDA approval.
  • Ongoing development of the G8 platform, expected to provide enhanced capabilities.

Market Expansion:

  • Expanded reimbursement for CGM in type 2 diabetes, covering an additional 5 million people in the U.S.
  • Noteworthy international coverage wins in markets such as France and New Zealand.

Future Outlook and Guidance:

  • Guidance for 2025 anticipates total revenue of $4.6 billion (14% growth).
  • Full-year gross profit margin expected to improve to 64-65%.
  • Focus on converting existing customer base to newer products (e.g., G7 and upcoming G8).

Strategic Initiatives:

  • Continuous emphasis on broadening CGM adoption among both insulin and non-insulin user populations.
  • Investment in generative AI technology within the Stella platform to enhance user engagement and insights.

Risks & Considerations:

  • Observations on competitive dynamics in the DME channel and reimbursement landscapes.
  • Potential impacts of economic conditions on healthcare spending.
  • The necessity to manage new product launches effectively, ensuring coverage and integration with existing systems.

Conclusion:

DexCom presents a solid growth trajectory with expansive opportunities in the CGM market, particularly highlighted by its strategic focus on expanding coverage, refining product offerings, and leveraging its innovative technologies. Investors should monitor execution on these plans as the company aims for continued growth in both domestic and international markets.

DexCom Earnings History

Earnings Calendar

FAQ

When is the earnings report for DXCM?
DexCom (DXCM) has scheduled its earnings report for May 01, 2025 after the markets close.

What is the DXCM price-to-earnings (P/E) ratio?
DXCM P/E ratio as of Apr 16, 2025 (TTM) is 46.70.

What is the DXCM EPS forecast?
The forecasted EPS (Earnings Per Share) for DexCom (DXCM) for the first fiscal quarter 2025 is $0.330.

What are DexCom's retained earnings?
On its balance sheet, DexCom reported retained earnings of $1.11 billion for the latest quarter ending Dec 31, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT DEXCOM
DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to i...
GOLDEN STAR
Ticker Change Signal Date
I
ISTB
$48.08
0.291% Apr 14
B
BSCS
$20.24
0.395% Apr 14
BAH
$108.78
2.31% Apr 11
K
$82.14
0.183% Apr 10
ESGR
$332.23
0.226% Apr 10

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE